<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03074591</url>
  </required_header>
  <id_info>
    <org_study_id>Charite</org_study_id>
    <nct_id>NCT03074591</nct_id>
  </id_info>
  <brief_title>Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>FAIR-HFpEF</acronym>
  <official_title>Effect of IV Iron (Ferric Carboxymaltose, Ferinject) on Exercise Tolerance, Symptoms and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Iron Deficiency With and Without Anaemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study addresses, whether treatment with IV iron for patients with heart failure with
      preserved ejection fraction (HFpEF) and iron deficiency (ID), both with or without anaemia,
      can improve exercise capacity as measured by 6-minute walking test (6-MWT) and symptoms while
      being safe
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All previous trials have excluded patients with HFpEF. This study addresses, whether
      treatment with IV iron for patients with heart failure with preserved ejection fraction
      (HFpEF) and iron deficiency (ID), both with or without anaemia, can improve exercise capacity
      as measured by 6-minute walking test (6-MWT) and symptoms while being safe. The FAIR-HFpEF
      study was designed to evaluate the efficacy of Ferinject® in improving symptoms of HFpEF in
      patients with ID. Analyses will focus both on subjective and objective measures as well as on
      patients with and without anaemia. Furthermore, the tolerability and safety of Ferinject®
      treatment will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>exercise capacity</measure>
    <time_frame>52 weeks</time_frame>
    <description>The difference of 6-minute walking distance in meters from baseline to end of study in symptomatic patients with HFpEF with documented ID compared to the control group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6min-walking distance</measure>
    <time_frame>52 weeks</time_frame>
    <description>Difference of 6-minute walking distance in meters from baseline end of study in symptomatic patients with HFpEF with documented ID compared to the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>52 weeks</time_frame>
    <description>Difference in quality of life in symptomatic patients with HFpEF with documented ID from baseline to end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>52 weeks</time_frame>
    <description>Difference in NYHA class from baseline to end of study in symptomatic patients with HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality and Heart failure-related hospitalization rates</measure>
    <time_frame>52 weeks</time_frame>
    <description>Effects on mortality and HF-related hospitalization rates in symptomatic patients from baseline to end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Iron-deficiency</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose 50Mg/Ml Inj 15Ml</intervention_name>
    <description>After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution for Injection</intervention_name>
    <description>In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is willing to participate and provides written informed consent;

          2. Age ≥18 years;

          3. Clinical diagnosis of heart failure with preserved ejection fraction (HFpEF) with LVEF
             ≥45% at screening or within 6 months prior to planned randomisation (assessed by
             echocardiography or MRI);

          4. Ambulatory for at least 7 days with NYHA class II or III at time of randomisation (the
             screening visit can take place at the end of a hospitalisation);

          5. Treated with a diuretic;

          6. Presence of atrial fibrillation (AF) at screening or randomisation is allowed in 2 out
             of 4 patients (calculated per centre);

          7. At screening or randomisation, presence of one of the following criteria:

               1. hospitalisation with a diagnosis of HF within 12 months prior to planned
                  randomisation; OR

               2. raised plasma levels of natriuretic peptides in a patient with sinus rhythm (i.e.
                  in patients without AF: NT-proBNP &gt;300 pg/mL or BNP &gt;100 pg/mL or MR-proANP &gt;120
                  pmol/L; in patients with AF: NT-proBNP &gt;600 pg/mL or BNP &gt;200 pg/mL or MR-proANP
                  &gt;250 pmol/l)

          8. Evidence of diastolic dysfunction at screening or randomisation, defined as:

               1. E/E' &gt;13; OR

               2. LA width ≥38 mm; OR

               3. LA length ≥50 mm; OR

               4. LA area ≥20 cm2; OR

               5. LA volume ≥55 ml; OR

               6. left atrial volume index &gt;28 mL/m2;

          9. Haemoglobin &gt;9.0 g/dL and ≤14.0 g/dL (at screening);

         10. ID with ferritin &lt;100 ng/mL or ferritin 100-299 plus TSAT &lt;20% (at screening);

         11. 6-minute-walking distance at baseline &lt;450 m (average of the last 2 documented tests
             within 8 weeks prior to planned randomisation that also need to be within 20% of each
             other).

        Exclusion Criteria:

          1. Unable to sign informed consent

          2. Any prior echocardiography measurement of LVEF &lt;40%;

          3. Clinical signs and symptoms of infection including fever &gt;38°C;

          4. Use of IV iron, erythropoietin or blood transfusions within the previous 60 days;

          5. Use of concurrent immunosuppressive therapy;

          6. History of acquired iron overload or haemochromatosis (or a first relative with
             haemochromatosis);

          7. Known hypersensitivity to FCM or any other IV iron product;

          8. Known bleeding or haemolytic anemia;

          9. Presence of any condition that precludes exercise testing, such as decompensated HF,
             significant musculoskeletal disease, unstable angina pectoris, obstructive
             cardiomyopathy, severe uncorrected valvular disease, or uncontrolled brady-arrhythmias
             or tachy-arrhythmias;

         10. Probable alternative diagnoses that in the opiniton of the investigator could account
             for the patient's HF symptoms such as severe obesity, primary pulmonary hypertension,
             or chronic obstructive pulmonary disease (COPD); hence, patients with the following
             are excluded:

               1. Severe COPD, i.e. with known FEV1 &lt;50%, requiring home oxygen therapy, or on
                  chronic oral steroid therapy;

               2. body mass index ≥40.0 kg/m2;

         11. Presence of uncontrolled atrial fibrillation with resting heart rate &gt;110/min;

         12. Presence of uncontrolled hypertension with blood pressure &gt;160/100 mm Hg;

         13. Renal replacement therapy;

         14. Concurrent therapy with an erythropoiesis stimulating agent;

         15. Known active malignancy;

         16. Known HIV or active hepatitis infection;

         17. Pregnancy;

         18. Patients, who may be dependent on the sponsor, the investigator or the trial sites,
             have to be excluded from the trial

         19. Lack of willingness to storage and disclosure of pseudonymous disease data in the
             context of the clinical trial.

         20. Participation in another clinical trial within previous 30 days and/ or anticipated
             participation in another trial during this study.

         21. Inability to fully comprehend and/or perform study procedures in the investigator's
             opinion;

         22. Persons staying at an institution due to order by a national body or a court of law.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfram Doehner, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan von Haehling, Dr</last_name>
    <phone>00495513920911</phone>
    <email>stephan.von.haehling@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Ebner, Dr</last_name>
    <phone>0049551398132</phone>
    <email>nicole.ebner@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Innere Medizin/Kardiologie</name>
      <address>
        <city>Nurnberg</city>
        <state>Bavaria</state>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jeserich, Dr</last_name>
      <email>mjeserich@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefässzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <state>Lower Saxony</state>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remppis, Prof</last_name>
      <email>ba.remppis@hgz-bb.de</email>
    </contact>
    <contact_backup>
      <last_name>Merle Siems</last_name>
      <email>m.siems@hgz-bb.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Göttingen</name>
      <address>
        <city>Gottingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan von Haehling, Dr</last_name>
      <email>stephan.von.haehling@med.uni-goettingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Ebner, Dr</last_name>
      <email>nicole.ebner@med.uni-goettingen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik für Kardiologie und Angiologie</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Bauersachs, Prof</last_name>
      <email>Bauersachs.Johann@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Karin Hohenleitner-Luehrsen, Dr</last_name>
      <email>Hohenleitner-Luehrssen.Karin@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Elbeklinikum Stade</name>
      <address>
        <city>Stade</city>
        <state>Lower saxony</state>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Philipp, Dr</last_name>
      <email>sebastian.philipp@elbekliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Philipp</last_name>
      <email>vanessa.philipp@elbekliniken.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Mainz St. Vincenz und Elisabeth Hospital Klinik für Innere Medizin 1</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Genth-Zotz, Prof</last_name>
      <email>Innere-Medizin-1@kkmainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Bärbel Käsberger</last_name>
      <email>b.kaesberger@icloud.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saarland University Medical Center</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Laufs, Prof</last_name>
      <email>ulrich@laufs.com</email>
    </contact>
    <contact_backup>
      <last_name>Anja Zickwolf</last_name>
      <email>Anja.Zickwolf@uks.eu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena Friedrich-Schiller-Universität Jena</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PC Schulze, Prof</last_name>
      <email>Romy.Scholze@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Doehner, Prof.</last_name>
      <email>wolfram.doehner@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Nadja Scherbakov, Dr</last_name>
      <email>nadja.scherbakov@charite.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Gielen, Prof</last_name>
      <phone>00495231725727</phone>
      <email>Stephan.Gielen@klinikum-lippe.de</email>
    </contact>
    <contact_backup>
      <last_name>Melanie Kriete</last_name>
      <email>Melanie.Kriete@klinikum-lippe.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Nutsias, Prof</last_name>
      <phone>00493452795763524</phone>
      <email>michael.noutsias@uk-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik für Kardiologie und Angiologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahir Karakas, Dr</last_name>
      <email>m.karakas@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Beatrix Mattes</last_name>
      <email>b.mattes@uke.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Doehner, W</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Iron deficiency</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

